好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Paradoxical Increase in Stroke Mortality among Asian Indians in United States
Cerebrovascular Disease and Interventional Neurology
P02 - (-)
019
BACKGROUND: Asian Indians are one of the largest groups of Asians living in the United States. Due to a paucity of data, we performed this study to better characterize the stroke mortality and risk factors among Asian Indians in the United States.
DESIGN/METHODS: Age-adjusted stroke mortality incidence, rate ratio with 95% confidence interval (CI), and average annual percentage change over 10 years were calculated using multiple-cause-of-death files for 2000 to 2009. Prevalence of risk factors was estimated from National Health and Interview Survey (2000-2001 and 2009-2010).
RESULTS: The annual incidence of stroke mortality in 2000 was lowest among Asian Indians (88 per 100,000) followed by American Indians and Alaska Natives (112 per 100,000), whites (301 per 100,000) and African Americans (312 per 100,000). Compared with whites, the stroke rate ratio was 0.6(95% CI 0.5-0.7) for Asian Indians. Significantly lower rates of hypertension and cigarette smoking were observed in Asian Indians in 2000-2001 (compared with whites). The average annual percentage change over 10 years was 13.5%, 0.9%, -2.5%, and -2.9% for Asian Indians, American Indians and Alaska Natives, whites, and African Americans, respectively.
CONCLUSIONS: The 10 year paradoxical increase in stroke mortality among Asian Indians (in contrast to other population subsets) requires focused understanding and efforts.
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Basit Rahim, MD (Virginia Commonwealth University Health System) No disclosure on file
Hamza I. Maqsood, MD (Dept of Neurology) Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.